BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25407517)

  • 21. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma.
    Aksenenko MB; Kirichenko AK; Ruksha TG
    Pathol Res Pract; 2015 Jul; 211(7):521-7. PubMed ID: 25888143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
    Menzies AM; Haydu LE; Visintin L; Carlino MS; Howle JR; Thompson JF; Kefford RF; Scolyer RA; Long GV
    Clin Cancer Res; 2012 Jun; 18(12):3242-9. PubMed ID: 22535154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TERT promoter mutations in melanoma survival.
    Nagore E; Heidenreich B; Rachakonda S; Garcia-Casado Z; Requena C; Soriano V; Frank C; Traves V; Quecedo E; Sanjuan-Gimenez J; Hemminki K; Landi MT; Kumar R
    Int J Cancer; 2016 Jul; 139(1):75-84. PubMed ID: 26875008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of
    van Ipenburg JA; Naus NC; Dubbink HJ; van Ginderdeuren R; Missotten GS; Paridaens D; Verdijk RM
    Br J Ophthalmol; 2021 Oct; 105(10):1454-1461. PubMed ID: 33127831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
    Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
    Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
    Ofner R; Ritter C; Heidenreich B; Kumar R; Ugurel S; Schrama D; Becker JC
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):613-617. PubMed ID: 27990595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of BRAF mutations in localized cutaneous melanoma.
    Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
    J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF mutation screening in melanoma: is sentinel lymph node reliable?
    Nardin C; Puzenat E; Prétet JL; Algros MP; Doussot A; Puyraveau M; Mougin C; Aubin F
    Melanoma Res; 2015 Aug; 25(4):328-34. PubMed ID: 26020488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
    Guo X; Xu Y; Zhao Z
    Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
    Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
    Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
    Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low frequency of BRAF and CDKN2A mutations in endometrial cancer.
    Salvesen HB; Kumar R; Stefansson I; Angelini S; MacDonald N; Smeds J; Jacobs IJ; Hemminki K; Das S; Akslen LA
    Int J Cancer; 2005 Jul; 115(6):930-4. PubMed ID: 15723290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanomas of unknown primary frequently harbor TERT-promoter mutations.
    Egberts F; Krüger S; Behrens HM; Bergner I; Papaspyrou G; Werner JA; Alkatout I; Haag J; Hauschild A; Röcken C
    Melanoma Res; 2014 Apr; 24(2):131-6. PubMed ID: 24463461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the BRAF V600E mutation in primary cutaneous melanoma.
    Inumaru JS; Gordo KI; Fraga Junior AC; Silva AM; Leal CB; Ayres FM; Wastowski IJ; Borges NF; Saddi VA
    Genet Mol Res; 2014 Jan; 13(2):2840-8. PubMed ID: 24535907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-genome landscapes of major melanoma subtypes.
    Hayward NK; Wilmott JS; Waddell N; Johansson PA; Field MA; Nones K; Patch AM; Kakavand H; Alexandrov LB; Burke H; Jakrot V; Kazakoff S; Holmes O; Leonard C; Sabarinathan R; Mularoni L; Wood S; Xu Q; Waddell N; Tembe V; Pupo GM; De Paoli-Iseppi R; Vilain RE; Shang P; Lau LMS; Dagg RA; Schramm SJ; Pritchard A; Dutton-Regester K; Newell F; Fitzgerald A; Shang CA; Grimmond SM; Pickett HA; Yang JY; Stretch JR; Behren A; Kefford RF; Hersey P; Long GV; Cebon J; Shackleton M; Spillane AJ; Saw RPM; López-Bigas N; Pearson JV; Thompson JF; Scolyer RA; Mann GJ
    Nature; 2017 May; 545(7653):175-180. PubMed ID: 28467829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.